Center for Translational and Public Health Genomics
The Center for Translational and Public Health Genomics (CTPHG) was created to bridge the gap between epidemiologic discoveries and their translation into clinical and public health applications to benefit cancer patients, individuals at elevated risk for cancer, and the general population. Leveraging the large patient population and healthy controls with comprehensive data and biospecimens and the rapid development of new high-throughput biomedical technologies that generate genomic information at an unprecedented pace, the Center contributes to the institutional commitment of personalized medicine by providing expertise in translational genomics for cancer risk, prevention interventions, progression from pre-malignancy to cancer, pharmacogenomics to predict therapeutic response, and survivorship and quality of life (QOL).
The Center for Translational and Public Health Genomics takes advantage of MD Anderson’s large patient population and its well established foundation of epidemiologic and genomic research to facilitate and support translation and public health genomics research.
The Center for Translational and Public Health Genomics will serve as an institutional hub for research and scientific exchange among investigators in translational epidemiology, public health genomics, pharmacogenomics, clinical outcomes, and survivorship research with an emphasis on inherited genetic variations.
To leverage the cancer patient population, facility expertise, and infrastructure of MD Anderson to establish the MD Anderson Cancer Patient Cohort (MDACPC). This cancer patient cohort is specifically designed to address the determinants of prognosis, progression, response, chemotherapy and radiation toxicity, survival, symptoms, quality of life, and other cancer-related outcomes by coupling biospecimen collection through the Blood Specimen Research Resource (BSRR), patient data from the Patient History Database (PHDB), and genomics expertise.
- To provide translational genomics support and expertise to studies within and outside the Division of Cancer Prevention and Population Sciences. Genomics plays an essential role in translating the findings from basic and population science to the clinic. The CTPHG will become a central node for the integration of these research activities within the Division and across the institution.
- To perform cutting edge research of germline genetic variations and intermediate phenotypes in relation to all aspects of the cancer continuum: prevention, risk, therapeutic response, toxicity, outcomes, and survivorship. These studies will extend to somatic genetic and molecular alterations that drive these processes.
- To perform functional genomics research, validating and functionally characterizing causal genetic variants and genes that could better inform development of molecular targets for chemoprevention and therapy.
- To apply novel statistical approaches to define gene-networks and construct prediction models for progression, risk, clinical outcomes, response to chemoprevention and therapy, and survivorship issues through the integration of epidemiological, clinical, and germline and somatic genetic data. These outcomes include progression from premalignant to malignant tissues, primary tumor, and secondary tumor development in cancer prevention trials, response to nicotine cessation therapy, tumor recurrence, response to treatment, survival, and QOL.
- The CTPHG will work closely with other programs in the Division of Cancer Prevention and Population Sciences, Duncan Family Institute for Cancer Prevention and Population Science, Personalized Cancer Therapy the Institute for Personalized Cancer Therapy, Institute for Cancer Care Excellence, Institute for Basic Science, as well as with other institutions within the Texas Medical Center and beyond.
- To provide consultation and service and to foster and stimulate collaborations within and outside MD Anderson and actively participate in multi-institutional consortium activities of translational epidemiological studies; to educate the clinical utility of pharmacogenetic knowledge and the incorporation of pharmacogenetic components into prevention and therapy clinical trials.